This CME/CE-certified audio and slide presentation will provide updates on the latest paradigms for the testing and management of HIV. The symposium will be conducted in an engaging format, in which the faculty and audience will navigate a series of questions on current management pathways, including testing; timing of initiation of treatment; initial and ongoing treatment options with current and new agents; and adherence and management of coinfections and comorbidities. In addition, the experts will look at the road ahead and discuss recent research in understanding the complications of HIV disease and treatment and future initiatives for potentially curing HIV and eradicating HIV reservoirs.

This program is designed for health care practitioners (physicians, physician assistants, nurse practitioners, and registered nurses) involved in the management of patients with HIV.

After completing this activity, the participant should be better able to:

• Implement the 2006 CDC recommendations for testing patients for HIV
  
• Identify disparities in regard to access of care in underserved areas and populations in the United States
  
• Implement the 2009 DHHS guidelines as they relate to treatment timing, initiation, and regimen selection for the optimal treatment for persons with HIV
  
• Discuss current and new agents for the treatment of HIV with respect to adherence, coinfection, and comorbidities
  
• Discuss advances in current research into understanding the complications of HIV disease and treatment
  
• Identify the role of inflammation and initiatives to potentially cure HIV and eradicate HIV reservoirs

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and HealthmattersCME. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Designation

This educational activity for 1.8 contact hours is provided by Postgraduate Institute for Medicine (PIM).

Accreditation Statements

Postgraduate Institute for Medicine (PIM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

John G. Bartlett, MD, has no real or apparent conflicts of interest to report, nor any financial relationships to disclose.

Calvin J. Cohen, MD, MS
Consulting Fees: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; Tibotec Therapeutics; Tobira Therapeutics
Contracted Research: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; Tibotec Therapeutics; ViiV Healthcare
Fees for Non-CME Services: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; Tibotec Therapeutics

Eric S. Daar, MD
Consulting Fees: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; ViiV Healthcare
Contracted Research: Abbott Laboratories; Merck & Co; Pfizer Inc

Charles B. Hicks, MD
Consulting Fees: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; Tibotec Therapeutics; ViiV Healthcare
Contracted Research: Bristol-Myers Squibb; Gilead Sciences, Inc; Merck & Co; Tibotec Therapeutics; ViiV Healthcare

Sally L. Hodder, MD
Contracted Research: Bristol-Myers Squibb; Gilead Sciences, Inc; Tibotec Therapeutics
Consulting Fees: Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences, Inc; Tibotec Therapeutics
Fees for Non-CME Services: Bristol-Myers Squibb
Stock: Merck & Co

Daniel R. Kuritzkes, MD
Consulting Fees: Abbott Laboratories; Avexa; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences, Inc; GlaxoSmithKline; Human Genome Sciences; Merck & Co; Oncolys; Pfizer Inc; Roche; Tobira; ViiV Healthcare; ViroStatics; VIRxSYS
Contracted Research: Gilead Sciences, Inc; Human Genome Sciences; Merck & Co

Paul E. Sax, MD
Consulting Fees: Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Pfizer
Contracted Research: GlaxoSmithKline; Merck; Tibotec Therapeutics

Valerie E. Stone, MD, MPH
Consulting Fees: Gilead Sciences, Inc; Tibotec Therapeutics

Mark Sulkowski, MD
Consulting Fees: Abbott; Anadys Pharmaceuticals, Inc; Boehringer Ingelheim; Genentech, Merck; Pfizer Inc; Roche Pharmaceuticals; Tibotec Therapeutics
Contracted Research: Abbott; Boehringer Ingelheim; Genentech; Johns Hopkins University; Merck; Tibotec Therapeutics; Vertex

Donna E. Sweet, MD, AAHIVS, MACP
Contracted Research: Bristol-Myers Squibb
Fees for Non-CME/CE: Bristol-Myers Squibb; Abbott; Bristol-Myers Squibb; Gilead Sciences, Inc; Pfizer Inc; Tibotec Therapeutics

The following PIM planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN; BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following HealthmattersCME managers and planners, James Murphy, Yaming Wang, and Carole Gabor, hereby state that they do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), HealthmattersCME, and Gilead Sciences, Inc, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, HealthmattersCME, and Gilead Sciences, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

There are no fees for participating and receiving CME/CE credit for this activity. During the period October 25, 2010 through October 25, 2011, participants must (1) read the learning objectives and faculty disclosures; (2) study the educational activity; (3) complete the posttest by going to http://www.cmeuniversity.com to register or login, clicking on “Find Post-tests by Course” on the navigation menu, selecting Course #7556, and recording the best answer to each question; and (4) complete the evaluation form and credit request.

• Internet Activity